title: Miniaturization of asymmetrical flow field-flow fractionation and application to studies on lipoprotein aggregation and fusion.
abstract: Asymmetrical flow field-flow fractionation (AsFlFFF), a technique that provides direct measurement of particle size and diffusion coefficient, is converted into miniaturized scale. In comparison with conventional AsFlFFF, the separation of proteins in miniaturized AsFlFFF is achieved within shorter time periods, with smaller sample amounts, and with lower mobile phase consumption. Minimization of the overloading and optimization of the separation efficiency are prerequisites to good results. Miniaturized AsFlFFF is applied to the measurement of particle sizes of high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL). The average hydrodynamic diameters at pH 7.4 in 8.5mM phosphate buffer containing 1mM EDTA and 150 mM NaCl are 8.6+/-0.5, 11.2+/-0.2, 22.1+/-0.7, and 48.9+/-7.5 nm for subgroups HDL3, HDL2, LDL, and VLDL, respectively. In addition, the effect of different factors on the aggregation and fusion of LDL particles is studied. LDL particle sizes are unaffected by the addition of up to 300 mM NaCl and by an increase of the carrier solution pH from 3.2 to 7.4, but treatment of LDL with alpha-chymotrypsin, sphingomyelinase, or copper sulfate leads to the formation of aggregated and fused LDL particles.
authors.affiliation: Laboratory of Analytical Chemistry, Department of Chemistry, University of Helsinki, FIN-00014 Helsinki, Finland.
authors.forename: Gebrenegus
authors.initials: G
authors.lastname: Yohannes
authors.forename: Mia
authors.initials: M
authors.lastname: Sneck
authors.forename: Sami J O
authors.initials: SJ
authors.lastname: Varjo
authors.forename: Matti
authors.initials: M
authors.lastname: Jussila
authors.forename: Susanne K
authors.initials: SK
authors.lastname: Wiedmer
authors.forename: Petri T
authors.initials: PT
authors.lastname: Kovanen
authors.forename: Katariina
authors.initials: K
authors.lastname: Oörni
authors.forename: Marja-Liisa
authors.initials: ML
authors.lastname: Riekkola
mesh_terms: D002918:Chymotrypsin; D019327:Copper Sulfate; D031521:Fractionation, Field Flow / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D008074:Lipoproteins / Q000737:chemistry* / Q000302:isolation & purification*; D008075:Lipoproteins, HDL / Q000737:chemistry / Q000302:isolation & purification; D053439:Lipoproteins, HDL2; D053440:Lipoproteins, HDL3; D008077:Lipoproteins, LDL / Q000737:chemistry / Q000302:isolation & purification; D008079:Lipoproteins, VLDL / Q000737:chemistry / Q000302:isolation & purification; D008904:Miniaturization / Q000295:instrumentation / Q000379:methods; D046912:Multiprotein Complexes; D009994:Osmolar Concentration; D010084:Oxidation-Reduction; D010316:Particle Size; D013108:Sphingomyelin Phosphodiesterase
chemical_list: D008074:Lipoproteins; D008075:Lipoproteins, HDL; D053439:Lipoproteins, HDL2; D053440:Lipoproteins, HDL3; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D046912:Multiprotein Complexes; D013108:Sphingomyelin Phosphodiesterase; D002918:Chymotrypsin; C117608:alpha-chymotrypsin; D019327:Copper Sulfate